PAVmed to Participate in BTIG Digital Health Forum
November 11 2022 - 8:25AM
Business Wire
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”, the
“Company”), a diversified commercial-stage medical technology
company operating in the medical device, diagnostics, and digital
health sectors, today announced that Lishan Aklog, M.D., PAVmed’s
Chairman and CEO, will participate in the Technologies Ushering in
Next-Generation Diagnostics, Therapies, and Surgeries virtual panel
discussion on November 21, 2022 from 12:00 pm to 12:55 pm EST at
the BTIG Digital Health Forum. Dr. Aklog will, in part, discuss
PAVmed’s majority-owned digital health subsidiary, Veris
Health.
In addition, PAVmed will host 1x1 virtual meetings during the
forum. Please contact your BTIG representative for access to the
panel discussion and to schedule a 1x1 meeting.
About PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology
company operating in the medical device, diagnostics, and digital
health sectors. Its major subsidiary, Lucid Diagnostics Inc.
(Nasdaq: LUCD), is a commercial-stage cancer prevention medical
diagnostics company which markets the EsoGuard® Esophageal DNA Test
and EsoCheck® Esophageal Cell Collection Device—the first and only
commercial tools for widespread early detection of esophageal
precancer to prevent esophageal cancer deaths. Lucid operates its
own CLIA-certified, CAP-approved molecular diagnostic laboratory,
LucidDx Labs and a network of Lucid Test Centers. Another major
subsidiary, Veris Health Inc., is a digital health company focused
on enhanced personalized cancer care through remote patient
monitoring using implantable biologic sensors with wireless
communication along with a custom suite of connected external
devices. The product pipeline also includes the CarpX® Minimally
Invasive Device for Carpal Tunnel Syndrome, EsoCure™ Esophageal
Ablation Device with Caldus™ Technology, which complements EsoGuard
and EsoCheck, NextFlo™ Intravenous Infusion Set, PortIO™
Implantable Intraosseous Vascular Access Device, and other earlier
stage technologies. For more information on PAVmed, please visit
PAVmed.com and follow PAVmed on Twitter, LinkedIn, and YouTube. For
more information on Lucid, please visit LucidDx.com and follow
Lucid on Twitter, and LinkedIn. For detailed information on
EsoGuard, please visit EsoGuard.com and follow EsoGuard on Twitter,
Facebook and Instagram.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risks and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of PAVmed’s and Lucid’s management, are subject to
risks and uncertainties, which could cause actual results to differ
from the forward-looking statements. Risks and uncertainties that
may cause such differences include, among other things, volatility
in the price of PAVmed’s and Lucid’s common stock; PAVmed’s Series
Z warrants; general economic and market conditions; the
uncertainties inherent in research and development, including the
cost and time required to advance PAVmed’s and Lucid’s products to
regulatory submission; whether regulatory authorities will be
satisfied with the design of and results from PAVmed’s and Lucid’s
clinical and preclinical studies; whether and when PAVmed’s and
Lucid’s products are cleared by regulatory authorities; market
acceptance of PAVmed’s and Lucid’s products once cleared and
commercialized; PAVmed’s and Lucid’s ability to raise additional
funding as needed; and other competitive developments. In addition,
new risks and uncertainties may arise from time to time and are
difficult to predict. For a further list and description of these
and other important risks and uncertainties that may affect
PAVmed’s and Lucid’s future operations, see Part I, Item 1A, “Risk
Factors,” in PAVmed’s and Lucid’s most recent Annual Report on Form
10-K filed with the Securities and Exchange Commission, as the same
may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly
Report on Form 10-Q filed by PAVmed or Lucid after its most recent
Annual Report and Lucid’s Registration Statement No. 333-259721
filed with the Securities and Exchange Commission. PAVmed and Lucid
disclaim any intention or obligation to publicly update or revise
any forward-looking statement to reflect any change in its
expectations or in events, conditions, or circumstances on which
those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221111005255/en/
Investors and Media Adrian K.
Miller PAVmed Inc. AKM@PAVmed.com
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Apr 2024 to May 2024
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From May 2023 to May 2024